Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 99 | ECE2024

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

Card image cap
We are pleased to announce that ECE 2024 will be held in Stockholm, Sweden from 11-14 May 2024. We will, once again, be offering the hybrid format next year so you can join us in person in Sweden or remotely with ECE@Home.

Rapid Communications

Rapid Communications 13: Late Breaking

ea0099rc13.1 | Rapid Communications 13: Late Breaking | ECE2024

MTHFR 677 TT and CT genotype related epigenetic changes and hyperhomocysteinemia in Hypothyroidism and its management, a family case report

Kvaratskhelia Tamar , Abzianidze Elene , Surmava Sandro , Kvaratskhelia Eka

Introduction: Hypothyroidism is a clinical syndrome resulting from a deficiency of thyroid hormones, which in turn results in a generalized slowing down of metabolic processes. There are consistent reports demonstrating that many diseases, including the thyroid gland dysfunction are associated with changes of serum homocysteine (tHcy) level, with its genetic and epigenetic causes.Case report: In 2018 we reported 51 and 52-year-old sisters diagnosed with ...

ea0099rc13.2 | Rapid Communications 13: Late Breaking | ECE2024

Comprehensive genetic analyses of sporadic and seemingly idiopathic hypoparathyroidism by whole-exome sequencing: Identification of novel GCM2 and AIRE mutations

Sahoo Saroj , Babu Takasi Anush , Mandal Kausik

Objective: We aimed to identify the genetic defect in patients labelled as sporadic and idiopathic hypoparathyroidism (HP) by using whole-exome sequencing (WES).Methods: Patients with sporadic nonsurgical HP, aged <30 years were recruited. Those with a known genetic or autoimmune aetiology were excluded from the study. Thirty such patients were screened for antibodies against interferon-α, a highly sensitive and specific marker of autoimmune pol...

ea0099rc13.3 | Rapid Communications 13: Late Breaking | ECE2024

Comparison of metyrapone, osilodrostat and ketoconazole in the therapy of endogenous Cushing’s syndrome: The MOSKETEER study

Detomas Mario , Ceccato Filippo , Simeoli Chiara , Dolce Pasquale , Aulinas Maso Ana , Gilis-Januszewska Aleksandra , Parasiliti Caprino Mirko , Bassiony Mohamed , Stelmachowska-Banaś Maria , Ferrante Emanuele , Pittaway James , Rubinstein German , Hanzu Felicia A , Pmglisi Soraya , Corsello Andrea , Antonini Simone , Sambula Lana , Minnetti Marianna , Haberbosch Linus , Deutschbein Timo , Dischinger Ulrich , Voltan Giacomo , Di Paola Nicola , Santos Vives Alicia , Minasyan Mari , Giordano Roberta , Fell Vanessa , Cylke-Falkowska Karolina , Mangone Alessandra , Plowman Christina , Vega Arturo , Braun Leah , Mazzarella Alessandro , Locantore Pietro , Faggiano Antongiulio , Terzolo Massimo , Lania Andrea , Kastelan Darko , Isidori Andrea , Reincke Martin , Bancos Irina , Arvat Emanuela , Webb Susan M , Carla Scaroni , Pivonello Rosario , Fassnacht Martin , Altieri Barbara

Background: Metyrapone, osilodrostat, and ketoconazole are steroidogenesis inhibitors used as second-line treatment in endogenous Cushing’s syndrome (CS). However, a direct comparison of these three drmgs is missing.Objective: To compare the efficacy of the three drmgs after short-term therapy (≤12 weeks) for CS.Methods: Multicenter, real-life retrospective study involving 20 centers worldwide. Patients with CS treated w...

ea0099rc13.4 | Rapid Communications 13: Late Breaking | ECE2024

Development and validation of an LC-MS/MS method to measure 7-alpha-hydroxy-4-cholesten-3-one (C4) for the assessment of bile acid dysregulation in PCOS

Atkins Jonathan S , Keevil Brian , Ludwig Christian , Hawley James M.

Introduction: 7α-Hydroxy-4-cholesten-3-one (C4) is the common intermediary of the primary bile acids (BAs). Its concentration in serum correlates with the rate of activity of hepatic CYP7A1 and therefore with the rate of hepatic BA production. Previous work has smggested a role for BA pool dysregulation in the metabolic syndrome and gut dysbiosis seen in polycystic ovary syndrome (PCOS). However, the mechanism of this is still to be elucidated. Here we report a novel LC-M...

ea0099rc13.5 | Rapid Communications 13: Late Breaking | ECE2024

Dose response relationship between Denosumab treatment and germ cell proliferation of humanized RANKL mice in vivo and in testicular tissue cultures

Krarup Knudsen Nadia , Hjorth Andreassen Christine , O'Brien Charles , Jorgensen Anne , Blomberg Jensen Martin

Today there exist no treatment that can improve semen quality in more than 85% of infertile men. Interaction between germ and Sertoli cells is critical for sperm production, and Denosumab, an inhibitor of RANKL, has previously been shown to stimulate sperm production in a fraction of infertile men. Here, we show in a humanized RANKL mouse that Denosumab dose dependently increase germ cell proliferation and testicular weight. RANKL was modified so it can be blocked by Denosumab...

ea0099rc13.6 | Rapid Communications 13: Late Breaking | ECE2024

The clinical profile of silent and subclinical somatotroph PitNETs according to the immunohistochemical staining

Solovey Mariana , Danevych Olena , Guk Mykola , Musulevska Valeria

Background: Somatotroph PitNETs represent a polymorph group of GH-secreting pituitary neuroendocrine tumors with great variety of clinical presentation, which may graduate from totally silent without clinical and biochemical signs of hormonal hypersecretion to functioning with subtle or classic acromegaly symptoms. The grade of GH and somatostatin receptors expressoin as well as the other pituitary hormones and receptors co-expression may contribute to the tumor biological beh...